Anti-dengue Virus NS1 Protein Monoclonal Antibodies


This technology may be used to detect dengue virus infections.

Problem Addressed

Dengue fever and the more severe dengue hemorrhagic fever and dengue shock syndrome are caused by the mosquito-borne dengue virus. It is estimated that 50-100 million people are infected with dengue virus annually and that 2.5 billion people are currently at risk for contracting this dangerous pathogen. Dengue virus has four antigenically distinct serotypes, so those infected with one serotype do not develop immunity to the others despite extensive cross-reactivity in serological tests. Further, increased risk of severe complications occurs with infection of more than one serotype. Accurate diagnosis of dengue virus serotypes is critical to individual patient care and proper outbreak management. Dengue virus serotypes are quite distinct at a nucleic acid level, so nucleic acid detection techniques (PCR) can distinguish the serotypes with high sensitivity. However, these techniques are not always possible in rugged environments because they require laboratory environments, special reagents, and skilled technicians. This technology includes a set of novel pairs of monoclonal antibodies that can be used provide accurate and specific diagnosis of infection by each of the four dengue serotypes in assays that are amenable to rugged environments.


This invention comprises matched capture/detection monoclonal antibody pairs that can distinguish between the different dengue virus serotypes and detect one or more of these serotypes in a biological sample. The target antigen is the NS1 glycoprotein. This invention includes diagnostic detection kits for dengue virus. Lateral flow assays or ELISAs are recommended but detection labels are flexible. Cell culture, and cell culture media,tissue extracts, bodily fluids, blood or derivatives or blood are suitable for diagnostic applications.


  • Antibodies compatible with a large number of detection labels
  • Highly-specific antibodies can distinguish between different serotypes of dengue as well as yellow fever and Zika viruses without cross-reactivity from the NS1 protein from yellow fever or Zika viruses
  • Accurate detection of serotypes allows study of virus infection dynamics as well as individual patient treatment and improved outbreak management

Intellectual Property

IP Type: Published PCT Application

IP Title: Anti-dengue virus ns1 protein monoclonal antibodies

IP Number: WO 2017-139587


IP Type: Granted US Patent

IP Title: Anti-dengue virus ns1 protein monoclonal antibodies

IP Number: 10,551,381


IP Type: Published US Patent Applicaiton

IP Title: Anti-dengue virus ns1 protein monoclonal antibodies

IP Number: US 2020-0363415